Johnson & Johnson (JNJ.DE)
| Previous close | 136.96 |
| Open | 136.42 |
| Bid | 136.58 x 0 |
| Ask | 136.64 x 0 |
| Day's range | 135.90 - 138.16 |
| 52-week range | 132.78 - 161.20 |
| Volume | |
| Avg. volume | 3,517 |
| Market cap | 328.416B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 21.69 |
| EPS (TTM) | 6.29 |
| Earnings date | 17 Jul 2024 |
| Forward dividend & yield | 4.55 (3.32%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
ZacksMerck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
- Yahoo Finance Video
How Medicare drug price negotiations could hit pharma stocks
As a string of negative headlines and promising new developments present ideal buying opportunities for investors, Josh Lipton and Julie Hyman perform a mid-year check on the pharmaceutical industry. Goldman Sachs senior biotechnology analyst Chris Shibutani joins Market Domination to break down the health of the pharmaceutical large-caps and unrecognized areas of opportunity in the sector. Shibutani says the industry is "quite healthy," but acknowledges there are always "cross currents." He points to "tremendous advancements" in biotechnology innovation rising to daunting unmet needs, from cancer to cardiovascular disease. The analyst points to "holy grail-like" opportunities such as obesity drugs, and notes improvements in chemotherapy and next-generation antibody-drug conjugates for cancer treatment. However, Shibutani explains that the Inflation Reduction Act may challenge the industry, as the landmark legislation stipulates drug price negotiation for Medicare that is "beginning to play out." For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy
PR NewswireNipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG). Patients treated with nipocalimab plus standard of care (SOC) achieved superiority over placebo plus SOC as measured by the primary endpoint of improvement in the MG-ADL score from baseline over 24 weeks. These data are included in a presentation and are among eight abstracts that Johnson & Johnson will present at the European Academ
